Navigation

Generalised anxiety disorder - quetiapine [ID347]

Quetiapine for the treatment of generalised anxiety disorder

Status: Suspended
Expected date of issue: TBC
Referral date: June 2010
Process: STA
Notes:

Scoped within Batch 10

NICE has been informed by the manufacturer, AstraZeneca, that they have withdrawn their licensing application for the above indication. Therefore this topic has been suspended and the committee discussion that was due to take place on 24 March 2011 has been cancelled.

We will continue to monitor any development and update this webpage if the situation changes.

Topic area:
  • Mental health and behavioural conditions
  • Public health
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Raisa Sidhu
Communications manager: Alice Law
Project manager: Liz Walker
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 9 December 2010
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

Consultees

 

Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • AstraZeneca (quetiapine)

Patient/carer groups

  • Anxiety UK

Professional groups

  • British Association for Psychopharmacology
  • Royal College of Nursing
  • Royal College of Pathologists

Others

  • Department of Health
  • Welsh Assembly Government

General

  • British National Formulary
  • Care Quality Commission
  • Department of Health, Social Services and Public Safety for Northern Ireland

Comparator manufacturers

  • Dr Reddy's Laboratories (fluoxetine, sertraline)
  • Eli Lilly (duloxetine, fluoxetine)
  • Pfizer (pregabalin, venlafaxine, sertraline, mirtazapine, paroxetine)

Relevant research groups

  • None

Evidence review group

  • National Institute for Health Research Health Technology Assessment Programme
  • School of Health & Related Research Sheffield (ScHARR)

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Key documents

This page was last updated: 28 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.